Background: Multiple pilot studies, including one in colorectal cancer patients, suggest that creatine, an amino acid derivative, augments muscle, improves strength, and thereby could palliate the cancer anorexia/weight loss syndrome.
Introduction
Over 50 clinical trials have tested creatine supplements and, in total, suggest this amino acid derivative improves strength, augments muscle mass, and leads to weight gain [1] . Replete in dietary sources such as meat and fish, creatine is integrated into human skeletal and cardiac muscle, brain, and other organs, playing a pivotal role in energy production by transporting the extra phosphate that converts adenosine diphosphate to adenosine triphosphate. Because the latter fuels daily activities and bodily functions, creatine phosphate serves an important role by maintaining this key energy source. Creatine is thought to improve athletic performance, thereby enhancing muscle bulk and weight gain. Furthermore, emerging research suggests that creatine has direct muscle effects. A study in healthy men demonstrated large shifts in mRNA expression after creatine supplementation with patterns indicative of cytoskeletal muscle remodeling [2] .
Such observations in healthy individuals spawned studies focused on patients with various disease states, such as congestive heart failure, Duchenne muscular dystrophy, McArdle's disease, amyotrophic lateral sclerosis, sarcopenia of aging as well as a small study in colon cancer [3] [4] [5] [6] [7] [8] . At times, these trials have suggested clinical benefit in accordance with that observed in healthy adults who take creatine supplements. However, such factors as limited sample sizes and heterogeneity of study populations prompted a meta-analysis to conclude 'larger clinical studies are needed to confirm these observations' and another review to conclude 'further research is required' [9, 10] .
The trial reported here was designed to determine whether creatine improves clinical outcomes among incurable cancer patients who are suffering from the cancer anorexia/weight loss syndrome. The latter is a debilitating, life-limiting syndrome; no intervention, apart from successful cancer treatment, reverses all aspects [11] . At best, progesterone analogs and corticosteroids improve appetite but fail to address patients' decline in functional status and compromised survival [11] . In view of the foregoing provocative clinical and mechanistic data, the mandate to pursue more definitive clinical trials with creatine, and a clear lack of therapeutic options in solid tumor patients who suffer from the cancer anorexia/weight loss syndrome, the current multiinstitutional, double-blind, placebo-controlled trial was undertaken.
Patients and methods

Overview
The North Central Cancer Treatment Group (NCCTG), a cooperative group funded by the National Cancer Institute and now known as the Alliance, conducted this trial. All institutions had their institutional review boards approve the study protocol (NCT00081250). All patients had to provide written informed consent at the time of enrollment.
Eligibility criteria
To be eligible, patients had to meet all the following criteria: (i) age !18 -years; (ii) incurable malignancy other than a primary brain tumor; (iii) life expectancy of !3 months, as per the judgment of the treating healthcare provider; (iv) an Eastern Cooperative Oncology Group performance score of 0-2; (v) patient-reported weight loss of at least 5 pounds (2.3 kg) over the preceding 2 months and/or a healthcare provider-estimated caloric intake of <20 calories/kg of body weight/day; (vi) alert and reliably able to take oral medication; and (vii) under the care of a healthcare provider who believed that weight gain would potentially benefit the patient, and the patient perceived weight loss as a problem. Concurrent chemotherapy and/or radiation therapy was permitted.
Patients were excluded with any one of the following: (i) ongoing tube feedings or parenteral nutrition; (ii) edema or ascites; (iii) recent (within the preceding month) or anticipated treatment with adrenal corticosteroids (except for short-term dexamethasone around the time of chemotherapy), androgens, progestational agents, or other appetite stimulants; (iv) obstruction of the alimentary canal, malabsorption, or intractable vomiting or ongoing radiation to the bowel or stomach; (v) serum creatinine above the institutional upper limit of normal; (vi) symptomatic or untreated brain metastases; (vii) insulin-requiring diabetes; (viii) pregnancy, nursing, or unwilling to use oral contraceptives; (ix) poorly controlled hypertension or congestive heart failure; or (x) creatine use at study entry.
At baseline, patients underwent a history, physical examination, and assignment of performance score. Serum creatinine, a hemogram, and, if appropriate, a pregnancy test were obtained at baseline. All initial testing and follow up was to be done in a nonhospital setting. Figure 1 . A total of 134 creatine-treated and 129 placebo-exposed patients were assessed for the primary endpoint. 
Stratification and randomization
In a double blind manner, patients were randomly assigned to creatine versus an identical-appearing placebo with the following stratification factors: (i) cancer type: lung cancer versus gastrointestinal cancer versus other; (ii) degree of weight loss in the previous 2 months: <10 pounds versus !10 pounds; (iii) planned or ongoing concurrent chemotherapy: yes versus no; (iv) sex: male versus female; (v) age: <50 years versus !50 years; and (vi) a previously utilized index that categorized patients' prognosis as good versus bad versus unsure [12] .
Description of intervention
Creatine monohydrate with 99% purity as assessed by high-performance liquid chromatography as per the manufacturer was used. Both the creatine and identical placebo were provided by Hi-Health in Scottsdale, AZ. The intervention was to start no later than 14 days after randomization.
Patients started with a loading dose of creatine/placebo powder at 20 g/day orally for days 1-5. A measuring scoop was provided, and patients were advised to add the powder to any beverage. On day 6, patients started 2 g/day orally and could continue with the intervention indefinitely as long as no deleterious effects were observed. This dose was based on previous pilot studies that suggested benefit [13] .
Instructions for dose reductions or intervention cessation were outlined in the protocol. A serum creatinine was checked during the loading dose, and, if this laboratory parameter increased beyond 1.5 times the baseline value, the intervention was discontinued. If at any point, patients manifested weight gain beyond 120% of their ideal body weight, then dosing was to be cut by 50% at the discretion of the patient's healthcare provider. If 'unacceptable' weight loss occurred after a dose reduction, the original dose could be resumed. Healthcare providers were allowed discretion in adjusting the dose based on other adverse events, as long as the rationale for doing so was outlined in the patient's study record.
Baseline and follow-up assessments
At baseline, patients completed previously validated questionnaires to assess weight and appetite and were provided a weight diary. These items were to be completed weekly for 4 weeks, and then monthly as long as the patient remained on the creatine/placebo. The questionnaires consisted of an NCCTG appetite questionnaire, the Functional Assessment of Anorexia/Cachexia Treatment (FAACT) instrument (version 4); a series of linear analog self-assessment (LASA) scales on overall quality of life, mental well-being, physical well-being, emotional well-being, and degree of social activity; and a previously utilized Frailty Index to assess extent and spectrum of daily activities [14, 15] . Furthermore, at baseline, patients underwent assessment of fist-grip strength with a JAMAR V R hydraulic hand dynamometer and bioelectrical impedance. The latter was measured with the HYDRA ECF-ICF device at 5 and 200 frequencies. Patients underwent this testing monthly while on study.
Adverse events were itemized regardless of perceived attribution with Common Terminology Criteria for Adverse Events (version 3). Events were assessed and recorded at least monthly but more frequently if a severe event occurred.
Statistical considerations
The primary endpoint was the percentage of patients who gained !10% of their baseline weight in each study arm by 1 month. Weight was assessed monthly over time. Secondary endpoints included the percentage of patients who manifested weight stability (within 5% of baseline at 1 month), appetite changes, quality of life assessment scores, fist-grip strength, bioelectrical impedance, and intervention-related adverse events. Secondary endpoints were assessed monthly. Overall survival was also assessed as a secondary endpoint.
Patients who developed edema or ascites were censored with respect to weight data, and patients who dropped out after initiating creatine/placebo but before the 1-month time point were considered treatment failures. A Fisher's exact test was used to analyze differences between study groups for the primary endpoint and for other categorical endpoints. Two sample t-tests or Wilcoxon methodology was employed to explore differences between arms for continuous variables, such as quality of life ratings. All testing was carried out using a two-sided hypothesis test and a 5% type I error rate.
Sample size calculations were derived from an anticipated detection of a 15% difference in the true percentage of patients able to gain more than 10% of their baseline weight if that percentage was no more than 16% in the inferior group. In other words, the study team anticipated a 10% baseline weight gain in 16% of the placebo-exposed patients and in 31% of the creatine-treated patients. A sample size of 125 patients per arm allowed for >80% power for detecting the above. Figure 2 . Over 1 month, only three patients gained !10% of their baseline weight: two in the creatine arm and the other in the placebo arm (P ¼ 1.00). Over time, no trends emerged to indicate that creatine was effective.
Results
Baseline and general follow-up data
A total of 302 patients were recruited. Of these, 263 were evaluable for the primary study endpoint (Figure 1 ). Baseline demographics that included age, gender, weight loss, and anticipated concurrent chemotherapy administration showed comparability between study arms ( Table 1 ). The median time on the intervention was not statistically different between study arms: 54.5 days versus 64 days in patients assigned to the creatine and placebo arms, respectively (P ¼ 0.14).
Efficacy outcomes
Within this entire cohort of 263 evaluable patients, only 3 gained !10% of their baseline weight over 1 month: two in the creatine arm and the other in the placebo arm (P ¼ 1.00). Over time, 5 (4%) patients in the creatine arm and 14 (11%) in the placebo arm gained !10% of their baseline weight (P ¼ 0.03). In terms of less than a 5% change in weight (gain or loss), 95 (71%) of creatine-treated patients and 88 (68%) of placebo-exposed patients manifested such weight stability at 1 month (P ¼ 0.64) (Figure 2) .
In response to the 1-month NCCTG appetite questionnaire response with items, such as (i) 'How would you compare your appetite now to what it was before your present illness?' (ii) 'What is your current food intake in comparison to before your present illness?' (iii) 'How would you rate/describe your appetite?' (iv) 'How is your appetite now in comparison to before you started the study medications?' and (v) 'What effect, if any, do you feel the study medications have had on your food intake?' no statistically significant differences in responses were observed in arms over time ( Table 2 ). The FAACT questionnaire generated similar negative neutral results, as did LASA scores when assessed as change from baseline (data not shown). One-month Frailty Index responses based on intervention revealed no statistically significant differences between groups (Table 3) .
Fist-grip strength and bioelectrical impedance were assessed in cohort subgroups. In terms of fist-grip strength, 89 creatinetreated and 92 placebo-exposed patients participated. The mean scores (standard deviation) among the patients in these respective arms at baseline were 25 kg (9.2) and 26 (9.9); P ¼ 0.42. At 1 month, these scores were similar at 25 (10.5) and 25 (11.0); P ¼ 0.76. Evaluating changes from baseline between arms at this 1-month interval also revealed no statistically significant differences between groups with a change of -0.2 (7.7) in the creatine arm and -0.8 (7.2) in the placebo arm; this comparison was also statistically insignificant (P ¼ 0.94). Bioelectrical impedance was carried out in a subgroup that included 20 creatine-treated patients and 15 placebo-exposed patients. Again, readings at baseline and 1 month and assessing changes over time revealed no statistically significant differences between study arms (data not shown).
Grade 3 and 4 hematologic and nonhematologic adverse events were not statistically different between arms in their frequency ( Table 4 ). The more frequent events included such symptoms as nausea, vomiting, abdominal pain, constipation, and shortness of breath. Four deaths occurred during active intervention on the creatine arm and seven on the placebo arm.
No statistically significant differences in survival were observed between the treatment arms: median survival (days): 230 versus 239 in the creatine and placebo arms, respectively (P ¼ 0.70 by log-rank test) (Figure 3) .
Discussion
This trial showed that creatine, as prescribed here does not treat the cancer anorexia/weight loss syndrome. Evaluating multiple clinical endpoints-including weight, appetite, fist grip strength, body composition, and survival-we observed that creatine does not improve outcomes. This agent joins a long list of others, such as infliximab, etanercept, dronabinol, omega 3 fatty acids, fluoxymesterone, pentoxifylline, and hydrazine sulfate, which have yielded disappointment [16] [17] [18] [19] [20] [21] . Importantly, the negative findings reported here do not negate earlier trials that portrayed creatine as a promising for a variety of other maladies, including sarcopenia of aging and other disease states. It is possible that the pathophysiology of the cancer anorexia/weight loss syndrome differs from that of these other disease entities. One might also argue that creatine supplementation might be more effective in a deficient state, and, at least a modicum of data suggests that cancer patients might not be deficient [22] . The current study should, however, motivate other investigators to pursue larger, more definitive trials, with clinically meaningful endpoints to determine assuredly whether creatine does have a role in treating these other muscle disorders.
This study has both strengths and weaknesses. With respect to weaknesses, one might argue that our enrollment of patients with marked weight loss selected for patients at late stages of the cancer anorexia/weight loss syndrome and that these patients had reached a point of nonreversal. Although we acknowledge that certain interventions might be more effective with earlier stage disease, the fact that this study showed absolutely no benefit with creatine indicates that further study of creatine for this specific syndrome might be difficult to justify. The strengths of this study are its robust sample size; randomized, double-blinded, placebocontrolled study design; and reliance on clinically important endpoints-all of which we believe counterbalance the above limitation. In this context, we view the results reported here as important and definitive.
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